奥扎格雷钠联合舒血宁治疗急性脑梗死的临床观察  

Clinical study on the treatment of acute cerebral infarction by combined injection of ozagrel sodium and Shuxuening

作　　者：邵锦根[1] 张旭[1] 

机构地区：[1]温州医学院附属第一医院神经内科,浙江温州325000

出　　处：《中国医院药学杂志》2011年第7期588-590,共3页Chinese Journal of Hospital Pharmacy

摘　　要：目的:观察奥扎格雷钠联合舒血宁注射液治疗急性脑梗死的临床疗效和对血小板活性的影响。方法:将86例急性脑梗死患者随机分为对照组和治疗组。对照组给予奥扎格雷钠注射液,治疗组给予奥扎格雷钠联合舒血宁注射液,各组均静脉滴注,qd,连续治疗14d。比较2组治疗前后神经功能缺损程度,判定临床疗效,并分别检测治疗前后血小板活性指标。结果:治疗组在治疗后第14天的总有效率与对照组比较差异有显著性(P<0.05);治疗组治疗后神经功能缺损程度评分、血小板活性指标均较治疗前有明显改善(P<0.05或P<0.01),且优于对照组(P<0.05或P<0.01)。结论:奥扎格雷钠联合舒血宁注射液治疗急性脑梗死安全有效。OBJECTIVE To observe the clinical efficiency and safety of ozagrel sodium combined with Shuxuening in the treatment of patients with acute cerebral infarction. METHODS 127 patients with acute cerebral infraction were randomly divided into control group, treatment group. The control group was given ozagrel sodium. The treatment group was given ozagrel sodium and Shuxuening （once a day for 14 days）. The scoring of nervous function defect before treatment and after treatment were conducted, and the therapeutic effects were evaluated in both groups. All the patients were observed for the level of platelet activation markers. RKSULTS There was significant difference in total effective rate between two groups （P〈0. 05）, The scorings of nervous function defect and the level of platelet activation markers in treatment group after treatment were significantly decreased, compared with those before treatment （P〈0. 05, P〈0. 01）, which were obviously better than that of control group （P〈0.05,P〈0.01）. CONCLUSION Ozagrel sodium combined with Shuxuening injection is safe and efficient in the treatment of acute cerebral infarction.

关 键 词：脑梗死 奥扎格雷钠 舒血宁 血小板 

分 类 号：R743.3[医药卫生—神经病学与精神病学]